Key Details
Annual ROE
-92.61%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 01, 2024Recent annual earnings:
Mar 01, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Screeners with IMGN included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Similar stocks
ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry as well.
ImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Does ImmunoGen (IMGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
From a technical perspective, ImmunoGen (IMGN) is looking like an interesting pick, as it just reached a key level of support. IMGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Shares of ImmunoGen Inc (NASDAQ: IMGN) close to doubled this morning after AbbVie Inc (NYSE: ABBV) said it will buy the cancer therapies company for $10.1 billion. ImmunoGen stock priced at a massive premium The all-cash transaction values each share of ImmunoGen at $31.26 – about a 100% premium on their previous close.
The Dow is sprinting to the finish line this November, ahead of a historically bullish month.
ImmunoGen (NASDAQ: IMGN ) stock is seeing massive gains on Thursday after the company announced an acquisition deal with AbbVie (NYSE: ABBV ). A press release from AbbVie reveals that ImmunoGen is being acquired for $31.26 per share in cash.
TM, PAY, WRB, MNDY and IMGN have been added to the Zacks Rank #1 (Strong Buy) List on November 29, 2023.
ImmunoGen, Inc. expects to convert the Accelerated Approval of its drug Elahere to "Full Approval" in the 1st half of 2024. Potential European approval of Elahere for treatment of patients with FRa-high platinum-resistant ovarian cancer expected late 2024, with commercialization following after. Full results from the single-arm phase 2 PICCOLO study, using Elahere for the treatment of patients with FRa-high platinum-sensitive ovarian cancer, expected mid-2024.
FAQ
- What is the primary business of ImmunoGen?
- What is the ticker symbol for ImmunoGen?
- Does ImmunoGen pay dividends?
- What sector is ImmunoGen in?
- What industry is ImmunoGen in?
- What country is ImmunoGen based in?
- When did ImmunoGen go public?
- Is ImmunoGen in the S&P 500?
- Is ImmunoGen in the NASDAQ 100?
- Is ImmunoGen in the Dow Jones?
- When was ImmunoGen's last earnings report?
- When does ImmunoGen report earnings?
- Should I buy ImmunoGen stock now?